-
Oct 16, 2024 | 
jdsupra.com | Logan Breed |Chris Fitzpatrick |Jill Ottenberg
The Communiqué mirrors many of the recent policy goals that the U.S. antitrust agencies have articulated with respect to competition in AI-related markets, and demonstrates how the priorities of the FTC and DOJ Antitrust Division are largely in line with their international counterparts on this issue.
-
Oct 15, 2024 | 
lexology.com | Logan Breed |Edith Ramirez |Chris Fitzpatrick |Jill Ottenberg
On October 3, 2024 the Federal Trade Commission (FTC) and Department of Justice Antitrust Division (DOJ or the Antitrust Division) participated in the G7 Competition Authorities and Policymakers Summit, which focused on promoting competition in artificial intelligence (AI)-related technologies, products and applications.
-
Sep 27, 2024 | 
jdsupra.com | Logan Breed |Chuck Loughlin |Jill Ottenberg
In December 2020, under its authority pursuant to 6(b) of the FTC Act, the FTC issued orders to various companies “requiring them to provide data on how they collect, use, and present personal information, their advertising and user engagement practices, and how their practices affect children and teens.” In the FTC’s September 2024 Report,1 the agency alleges that companies: Collect and “indefinitely retain troves of data from and about users and non-users” in ways that “consumers might not...
-
Aug 29, 2024 | 
lexology.com | Philip Katz |Chuck Loughlin |Gary Veron |Komal Karnik Nigam |Ilana Kattan |Jason Conaty | +3 more
This is the fourth comment related to the pharmaceutical industry the FTC has submitted to various agencies since the beginning of 2024, and part of a broader effort by the FTC to prioritize “safeguarding fair competition and rooting out unlawful business practices in health care markets.”[1] FTC says FDA’s Draft Guidance on interchangeability will increase competition in biologic marketplaces Under the Public Health Service Act, the standard for interchangeability is that a biosimilar “can...
-
Jul 5, 2024 | 
lexology.com | Lauren Battaglia |Logan Breed |Michael DeLarco |George Ingham |Tao Leung |Chuck Loughlin | +1 more
On July 3, 2024, a Texas federal judge issued a preliminary injunction postponing the September 4, 2024 effective date of the Federal Trade Commission (FTC)’s final rule banning non-compete agreements (the Non-Compete Rule) as to plaintiffs Ryan, LLC, the U.S. Chamber of Commerce, Business Roundtable, Texas Association of Business, and Longview Chamber of Commerce.
-
Jun 4, 2024 | 
jdsupra.com | Ashley Howlett |Chuck Loughlin |Jill Ottenberg
The May 2024 RFI is in-line with the Agencies’ shift towards a holistic approach to analyzing transactions that considers not only the immediate competitive effects of the transaction, but also the acquiror’s history and current or future strategic initiatives. The 2023 Merger Guidelines—finalized by the Agencies in December 2023— specifically address serial acquisitions. Guideline 8 provides that “. . .
-
May 6, 2024 | 
lexology.com | David Fox |Philip Katz |Chuck Loughlin |Gary Veron |Jason Conaty |Ilana Kattan | +2 more
On April 30, 2024, the Federal Trade Commission (FTC) announced that it sent a new set of warning letters to ten pharmaceutical companies. The letters inform the companies that the FTC has notified the Food and Drug Administration (FDA) that the Commission is disputing 300 allegedly “improper or inaccurate” patent listings in the FDA Orange Book.
-
Apr 8, 2024 | 
jdsupra.com | Ilana Kattan |Chuck Loughlin |Jill Ottenberg
On March 22, 2024, the FTC filed an amicus brief in support of a generic drugmaker that was sued by a brand manufacturer for patent infringement related to an asthma inhaler.2 The generic manufacturer filed antitrust counterclaims alleging that the brand manufacturer improperly listed patents for dose counters and inhaler devices in the FDA’s Orange Book as a way to delay generic entry.
-
Feb 6, 2024 | 
jdsupra.com | Logan Breed |Chuck Loughlin |Jill Ottenberg
February 6, 2024 Logan Breed, Chuck Loughlin, Jill Ottenberg, Edith Ramirez Hogan Lovells + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: On January 25, 2024 the Federal Trade Commission (FTC) hosted a Technology Summit focused on generative artificial intelligence (AI) and other innovative technologies to address how control over key inputs—like data, chips, and cloud computing resources—could undermine competition.1 The summit...
-
Feb 5, 2024 | 
lexology.com | Edith Ramirez |Chuck Loughlin |Logan Breed |Jill Ottenberg
On January 25, 2024 the Federal Trade Commission (FTC) hosted a Technology Summit focused on generative artificial intelligence (AI) and other innovative technologies to address how control over key inputs—like data, chips, and cloud computing resources—could undermine competition.1 The summit coincided with an announcement that the FTC is launching a study regarding recent investments and partnerships involving generative AI companies and major cloud service providers to “shed light” on...
